Strategies to improve drug development efficiency through regulatory interactions, minimizing the placebo effect and improving data integrity within a phase 3 study of tozadenant in Parkinson’s disease patients with motor fluctuations (TOZ-PD)
Objective: To identify and implement strategies to improve the efficiency of drug development in Phase 3 studies. Background: Conducting global clinical trials can be challenging,…Risk factors for premature withdraw from the LS-1 PD study
Objective: To identify risk factors for premature withdrawal from a large, multi-center Parkinson's disease clinical trial of possible neuroprotection. Background: Premature withdrawal (PW) of subjects…Effects of subthalamic deep brain stimulation in motor and nonmotor function in Parkinson’s disease patients with parkin mutation
Objective: The aim of our study was to evaluate prospectively the changes in motor, nonmotor symptoms (NMS) and quality of life produced by subthalamic deep…Deep brain stimulation effect on the quality of life of individuals with Parkinson’s disease
Objective: To identify the perception of QOL in individuals with PD pre and post DBS. Background: The DBS is one type of effective treatment in…The study of clinical outcome of deep brain stimulation for the idiopathic Parkinson’s disease at 6 months follow-up
Objective: The aim of this study was to assess the motor and psychiatric outcomes at 6 months after subthalamic nucleus deep brain stimulation (STN-DBS) in…Subthalamic nucleus deep brain stimulation modulate catecholamine levels with significant relations to clinical outcome after surgery in patients with Parkinson’s disease
Objective: Because subthalamic nucleus deep brain stimulation is effective in L-3,4-dihydroxyphenylalanine responsive patients with Parkinson's disease (PD), the preoperative catecholamine levels may affect the effect…Bilateral subthalamic nucleus deep-brain stimulation (STN-DBS) in the management of idiopathic Parkinson’s disease: Results of our first 20 cases
Objective: Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is widely accepted as a treatment for advanced Parkinson's disease (PD). However, published studies were…Effect of unilateral subthalamic deep brain stimulation in highly asymmetric Parkinson’s disease: 7- year follow-up
Objective: To evaluate the long-term outcome of unilateral STN DBS in highly asymmetric patients with PD. Background: Unilateral STN DBS is suggested to be a…Real-world safety of deep brain stimulation in patients with ≤7.5 years between disease onset and device implant
Objective: The intent of this analysis was to characterize real-world safety of deep brain stimulation (DBS) in patients with ≤7.5 years between Parkinson's disease (PD)…DBS targeting: Validation of 3T MR image guided targeting using post-mortem 17T MR microscopy
Objective: This work helps validate the utility of direct targeting using 3T T1 inverted sequences with atlas application during planning for DBS electrode placement. We…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.